Qianjiang Yongan Pharmaceutical Co., Ltd.

SZSE:002365 Stock Report

Market Cap: CN¥2.4b

Qianjiang Yongan Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Qianjiang Yongan Pharmaceutical's earnings have been declining at an average annual rate of -12.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 0.3% per year.

Key information

-12.6%

Earnings growth rate

-12.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-0.3%
Return on equity-0.7%
Net Margin0.2%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Investors Aren't Buying Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Revenues

Feb 27
Investors Aren't Buying Qianjiang Yongan Pharmaceutical Co., Ltd.'s (SZSE:002365) Revenues

Revenue & Expenses Breakdown
Beta

How Qianjiang Yongan Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:002365 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24858112642
31 Dec 23973-1217542
30 Sep 231,1422526744
30 Jun 231,2148027142
31 Mar 231,36110528040
01 Jan 231,46214024740
30 Sep 221,56318714247
30 Jun 221,68017714949
31 Mar 221,66415115750
01 Jan 221,56510816453
30 Sep 211,4077323654
30 Jun 211,3045920954
31 Mar 211,26810819555
31 Dec 201,17310616847
30 Sep 201,25213414644
30 Jun 201,30715014546
31 Mar 201,3108813149
31 Dec 191,3709014054
30 Sep 191,2879613845
30 Jun 191,14310513735
31 Mar 191,05713913128
31 Dec 181,00517812624
30 Sep 181,01616414930
30 Jun 181,01116814326
31 Mar 1898215215016
31 Dec 1793313314710
30 Sep 177661321142
30 Jun 176881001050
31 Mar 1760679930
31 Dec 1654962920
30 Sep 1656750900
30 Jun 1654439940
31 Mar 1654121920
31 Dec 1555618900
30 Sep 1559819890
30 Jun 1568125810
31 Mar 1566136750
31 Dec 1465832720
30 Sep 1459429610
30 Jun 1456223610
31 Mar 1453514610
31 Dec 1352323610
30 Sep 1354241610
30 Jun 1349655570

Quality Earnings: 002365 has a large one-off loss of CN¥59.0M impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: 002365's current net profit margins (0.2%) are lower than last year (7.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002365's earnings have declined by 12.6% per year over the past 5 years.

Accelerating Growth: 002365's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002365 had negative earnings growth (-98.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).


Return on Equity

High ROE: 002365's Return on Equity (-0.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.